Sunday, October 9

Elan surges on Tysabri safety study findings

RTE Business -CLICK FOR COMPLETE ARTICLEShares in Elan surged by 20% on the Dublin stock market today after the drugs company and its partner for the development of the MS drug Tysabri, Biogen Idec, said a safety study had resulted in no new confirmed cases of the progressive multifocal leukoencephalopathy (PML) brain disease in MS patients.

The two companies have previously reported three confirmed cases of PML, two of which were fatal.

The ongoing safety evaluation in Crohn's disease and rheumatoid arthritis is on schedule to be completed by the end of the summer, the two companies added. They will then make submissions to regulatory authorities in early autumn.

Elan and Biogen also said that the companies are taking preliminary steps to restart clinical trials in MS.